Efficacy of Baricitinib in Patients With Different Degrees of Severe Alopecia Areata: 52-Week Results From BRAVE-AA1 and BRAVE-AA2
June 2023
in “
British Journal of Dermatology
”
Studysummary In this study, baricitinib showed promising results in improving scalp, eyebrow, and eyelash hair loss in adults with severe and very severe alopecia areata over 52 weeks.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on academic.oup.com →